ENDORADS
Research type
Research Study
Full title
Early eNDOcrine intervention after brain RADiotherapy feasibility Study
IRAS ID
358898
Contact name
Martin McCabe
Contact email
Sponsor organisation
University of Birmingham
Duration of Study in the UK
3 years, 0 months, 0 days
Research summary
The ENDORADS study will increase how often patients will have their hormone levels tested following radiotherapy treatment. Currently patients will have their hormone levels tested a year after radiotherapy treatment has ended. When patients are registered on the ENDORADS study they will have their hormones tested every 4 months, for two years, after the end of radiotherapy. The study will determine if patients develop hormonal issues earlier than current testing detects and therefore allow for earlier treatment where the patients medical team think it is necessary. By treating hormonal issues earlier, long-term side effects may be reduced. As a feasibility study, ENDORADS will determine if the more regular testing is acceptable for patients and the hospitals and look at the barrier to testing more regularly.
REC name
West of Scotland REC 1
REC reference
25/WS/0153
Date of REC Opinion
7 Nov 2025
REC opinion
Further Information Favourable Opinion